Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 3/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP14 | P50281 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 3/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054144 | 1.00 | CTSS (0.35) | CTSSCTSKBTKMMP1MMP9 | |
| SCHEMBL1054148 | 1.00 | CTSS (0.35) | CTSSCTSKBTKMMP1MMP9 | |
| SCHEMBL1054147 | 1.00 | CTSS (0.35) | CTSSCTSKBTKMMP1MMP9 | |
| SCHEMBL21260539 | 0.89 | AAK1 (0.35) | CTSSCTSKBTKMMP1MMP9 | |
| SCHEMBL8775461 | 0.89 | TSHR (0.38) | CTSSCTSKBTKMMP1MMP9 | |
| SCHEMBL13006283 | 0.89 | TSHR (0.38) | CTSSCTSKBTKMMP1MMP9 | |
| SCHEMBL28642858 | 0.89 | TSHR (0.38) | CTSSCTSKBTKMMP1MMP9 | |
| SCHEMBL21458953 | 0.89 | TSHR (0.38) | CTSSCTSKBTKMMP1MMP9 | |
| SCHEMBL10149436 | 0.88 | AAK1 (0.39) | CTSSAAK1PYGLMMP13KMT2A | |
| SCHEMBL28910478 | 0.85 | EPHX1 (0.36) | CTSSCTSKHDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12440706-B2 | Conjugated chemical inducers of degradation and methods of use | GENENTECH, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4055019-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12202829-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20250002489-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| CN-112218859-A | Modulators of proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
| CN-102558165-B | Smac peptidomimetics useful as iap inhibitors | NOVARTIS AG | 2014-08-13 | — | — | CN | disclosed |
| EP-2440549-A1 | 2, 3-DIHYDRO-1H-INDENE COMPOUNDS AND THEIR USE TO TREAT CANCER | AstraZeneca AB (SE) | 2012-04-18 | — | — | EP | disclosed |
| WO-2011057477-A1 | TETRAPEPTIDE ANALOGS, PREPARATION METHOD AND USE THEREOF | 上海艾力斯医药科技有限公司 (CN) | 2011-05-19 | — | — | WO | disclosed |
| US-20100317593-A1 | 2,3-DIHYDRO-1H-INDENE COMPOUNDS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| WO-2010142994-A1 | 2, 3-DIHYDRO-1H-INDENE COMPOUNDS AND THEIR USE TO TREAT CANCER | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | WO | disclosed |
| CN-101595121-A | Pyrrolidine derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2009-12-02 | — | — | CN | disclosed |
| CN-101511860-A | SMAC peptidomimetics useful as IAP inhibitors | NOVARTIS AG (CH) | 2009-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002489-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | ADRM1, PSMD7, UBQLN2 | CTSS 571/4885CTSK 189/4885BTK 3128/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | CTSS 792/4885CTSK 1059/4885BTK 3527/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | CTSS 1383/4885CTSK 2648/4885BTK 2626/4885 |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | CTSS 545/4885CTSK 982/4885BTK 3351/4885 |
| US-20100317593-A1 | 2,3-DIHYDRO-1H-INDENE COMPOUNDS | BIRC2, BIRC5, BIRC8 | CTSS 2279/4885CTSK 1528/4885BTK 4832/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | CTSS 2670/4885CTSK 2959/4885BTK 1214/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | CTSS 845/4885CTSK 747/4885BTK 1/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | CTSS 898/4885CTSK 851/4885BTK 1/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | CTSS 983/4885CTSK 1835/4885BTK 2154/4885 |
| US-12202829-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | CTSS 3002/4885CTSK 2831/4885BTK 2960/4885 |
| US-12440706-B2 | Conjugated chemical inducers of degradation and methods of use | ADRM1, SSB, FCER2 | CTSS 727/4885CTSK 708/4885BTK 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.